The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Open accessAbstract
Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial.Methods We did a single-arm, open-label, phase 1/2 trial of sirolimus in patients with active systemic lupus erythematosus disease unresponsive to, or intolerant of, conventional medications at the State University of New York Upstate Medical University (Syracuse, NY, USA). Eligible participants (aged ≥18 years) had active systemic lupus erythematosus fulfilling four or more of 11 diagnostic criteria defined by the American College of Rheumatology. We excluded patients with allergy or intolerance to sirolimus, patients with life-threatening manifestations of systemic lupus erythematosus, proteinuria, a urine protein to creatinine ratio higher than 0·5, anaemia, leucopenia, or thrombocytopenia. Patients received oral sirolimus at a starting dose of 2 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL. Patients were treated with sirolimus for 12 months. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. The primary efficacy endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Blood samples of 56 matched healthy individuals were obtained as controls for immunobiological outcomes monitored at each visit. The primary efficacy endpoint was assessed in all patients who completed 12 months of treatment, and all patients who received at least one dose of treatment were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00779194.Findings Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p<0·001) and the mean total BILAG index score decreased from 28·4 (12·4) at enrolment to 17·4 (10·7) after 12 months of treatment (p<0·001). The mean daily dose of prednisone required to control disease activity decreased from 23·7 mg (SD 9·6) to 7·2 mg (2·3; p<0·001) after 12 months of treatment. Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. CD8+ memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol (Z=-2·50, p=0·012), neutrophil counts (Z=-1·92, p=0·054), and haemoglobin (Z=-2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment (Z=2·06, p=0·0400).Interpretation These data show that a progressive improvement in disease activity is associated with correction of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment. Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus.Funding Pfizer, the National Institutes of Health, and the Central New York Community Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, mTOR blockade in patients with SLE treated with N-acetylcysteine or rapamycin reduces both pro-inflammatory T cells and disease activity85,260, suggesting that dietary supplementation or drugs that regulate mitochondrial dynamics might constitute novel therapeutic avenues for mitigating autoantibody production in SLE.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [260]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,814
Navarra, S., Guzmán, R., Gallacher, A., Hall, S., Levy, R. A., Jimenez, R., Li, E. K., Thomas, M., Kim, H., Leon, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,078
Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691
Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis
Xia, J., & Wishart, D. S. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.11 · Cited by 1,560
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Cited by
Sorted by citations
Items 301–400 of 411
Erythrocyte-derived mitochondria take to the lupus stage
Lepelley, A., & Crow, Y. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.08.008 · Cited by 7
The mTOR pathway in the antiphospholipid syndrome
Ji, L., Zhang, Z., & Perl, A. (2023) · Medical Review · doi:10.1515/mr-2023-0033 · Cited by 7
Self-citationNovel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus
Mizui, M., & Kono, M. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110182 · Cited by 8
Emerging areas for therapeutic discovery in SLE
Maria, N. I., & Davidson, A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.09.004 · Cited by 8
Altered Tregs and oxidative stress in pregnancy associated lupus
Pannu, N., Singh, R., Sharma, S. K., Chopra, S., & Bhatnagar, A. (2019) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-019-0082-8 · Cited by 7
Tian, J., Wang, Z., Tang, Z., Zhu, H., & Sun, L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03731-1 · Cited by 6
Yin, H., Zhou, S., Shen, K., Chen, H., Yang, M., Deng, Y., Chang, C., & Wu, H. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09109-3 · Cited by 6
Metabolic traits of T cells and the implications in autoimmune diseases
Zhou, Y., Zhou, Y., Zhu, Q., Guo, W., & Li, C. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.103989 · Cited by 6
Liu, Y., Xiang, L., Cheng, R., & Pan, S.-Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795760 · Cited by 6
Zhang, Y., Yao, Q., Wang, D., Cassady, K. M., Zou, W., Xiong, J., Yao, H., Deng, X., Wang, P., Yang, S., et al. (2023) · Platelets · doi:10.1080/09537104.2023.2277831 · Cited by 6
Wang, D., Li, Y., Zhang, C., He, S., & Chen, X. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13778 · Cited by 6
Lu, J., Ding, M., Cui, S., Yang, L., Zhao, J., He, J., Wang, X., Chang, F., Liu, X., Wang, Q., et al. (2025) · Central European Journal of Immunology · doi:10.5114/ceji.2025.149252 · Cited by 5
Bai, W., Peng, L., Gui, Y., Chen, Y., Duan, X., Li, X., Zhang, H., Huo, Y., Xu, J., Yang, P., et al. (2025) · Rheumatology and Immunology Research · doi:10.1515/rir-2025-0011 · Cited by 11
Gu, H., Mou, W., Chen, Z., Xie, X., Yao, J., Zhang, R., Wu, R., & Gui, J. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1014249 · Cited by 5
Liu, X., Mao, Z., Yuan, M., Li, L., Tan, Y. C. R. S., Qu, Z., Chen, M., & Yu, F. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000896 · Cited by 5
T-cell biology, tolerance, and regulation
Cava, A. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00031-2 · Cited by 5
Zhang, L., Cui, J., & Zhang, L. (2022) · Medicine · doi:10.1097/md.0000000000031551 · Cited by 5
Taurine corrects lupus CD4+ T cell imbalance through inhibition of mTORC1 signaling
Huang, S., Cui, Y., Zhang, Y., Deng, H., Liu, S., & Feng, X. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00936-x · Cited by 4
Gao, Y., Fan, X.-Z., Li, R., & Zhou, X. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.118778 · Cited by 4
Chen, H., Qiu, X., Wang, J., & Wei, H. (2022) · Medicine · doi:10.1097/md.0000000000031997 · Cited by 4
2‐deoxy D‐glucose treatment does not elicit a hair growth response in alopecia areata
Sundberg, J. P., Silva, K. A., Kennedy, V. E., Wilson, J. J., Gott, N. E., Sundberg, B. A., & Roopenian, D. C. (2019) · Experimental Dermatology · doi:10.1111/exd.14008 · Cited by 4
Editorial: New biomarkers for the diagnosis and treatment of systemic lupus erythematosus
Perl, A., Agmon‐Levin, N., Crispín, J. C., & Jørgensen, T. N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009038 · Cited by 4
Self-citationImpact of Rapamycin on Longevity: Updated Insights
Sanati, M., Afshari, A. R., Aminyavari, S., Banach, M., & Sahebkar, A. (2024) · Archives of Medical Science · doi:10.5114/aoms/191565 · Cited by 3
Zhang, J., Liao, B., Wang, X., & Liu, W. (2025) · Immunological Investigations · doi:10.1080/08820139.2025.2475816 · Cited by 3
Toumi, E., Bestion, E., Militello, M., Lépidi, H., Plauzolles, A., Bardin, N., Bertin, D., Chiche, L., Mège, J., Halfon, P., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70058 · Cited by 3
Zhang, S., Li, Y., Yang, B., Teymur, A. A., Atrooz, F., Majd, S., Mohan, C., Salim, S., & Wu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-21877-8 · Cited by 3
Perl, A., & Banki, K. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01421-2 · Cited by 3
Self-citationMetabolic control of pathogenesis in autoimmune diseases
Perl, A., & Morel, L. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00059-x · Cited by 3
Self-citationHigh disease activity correlate with decreased serum calcium in systemic lupus erythematosus
Du, X., Che, Y., Yuan, Y., Zhang, Q., Zou, X., & Huang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-93771-2 · Cited by 3
The pathogenic role of metabolism in Sjögren's syndrome
Colafrancesco, S., Simoncelli, E., Priori, R., & Bombardieri, M. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/hhbqej · Cited by 3
Du, K., He, G., Huang, F., Zhang, X., Zhang, X., Jie, J., Huang, C., Wu, Y., Fan, H., Lin, Z., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.165057 · Cited by 3
Association between glomerular mTORC1 activation and crescents formation in lupus nephritis patients
Ding, Y., Luan, Z.-Q., Mao, Z., Qu, Z., & Yu, F. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109288 · Cited by 2
Unraveling the Pleiotropic Role of High‐Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases
Giacaglia, M. B., Pires, V., Santana, M. D. F. M., & Passarelli, M. (2024) · International Journal of Rheumatology · doi:10.1155/2024/1896817 · Cited by 2
Wang, F., Yang, C., Shu, Y., Lin, C., Yao, Y., Li, Y., Zhang, Y.-M., Wang, X., Meng, L., Cheng, X.-Y., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04173-0 · Cited by 2
Glycometabolic reprogramming of immune cells in autoimmune diseases
Lin, J., Yang, F., Zheng, Y., Wang, X., Fan, X., & Yang, L. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103876 · Cited by 2
Liu, X., Wang, C., & Guan, X. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103488 · Cited by 2
Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis
Yang, Y.-S., Li, X.-R., Wang, Z.-M., Zheng, L., Li, J., Cui, X.-L., Song, Y., Ma, J., Guo, H., Gao, L., et al. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i6.104073 · Cited by 2
Berner, K., Oz, N., Kaya, A., Acharjee, A., & Berner, J. E. (2024) · Aging · doi:10.18632/aging.206033 · Cited by 2
Li, R., Xu, W., Liu, X., Fu, L., Lan, Y., Feng, S., & Huang, A. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70156 · Cited by 2
Targeting Autophagy with Small-Molecule Modulators in Immune-Related Diseases
Zhang, L., & Liu, B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-0606-2_11 · Cited by 2
Metabolic and mitochondrial dysfunction in SLE
Perl, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00014-2 · Cited by 2
Self-citationExploratory study of autophagy inducer sirolimus for childhood cerebral adrenoleukodystrophy
Luo, X., Liu, L., Wang, Q., Wang, Y., Wang, J., Yang, X.-Y., Li, S., & Zou, L. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1187078 · Cited by 2
Rapamycin Augmentation of Chronic Ketamine as a Novel Treatment for Complex Regional Pain Syndrome
Sharma, A., Tajerian, M., & Berner, J. E. (2023) · Cureus · doi:10.7759/cureus.43715 · Cited by 2
Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
Huo, A.-X., Chen, W., Liu, Y., Gao, P., & Li, J. (2019) · Medicine · doi:10.1097/md.0000000000017607 · Cited by 2
Innovative Trials and New Opportunities in SLE
Chaichian, Y., & Wallace, D. J. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.010 · Cited by 2
Unveiling Molecular Mechanisms Underlying Obesity‐Associated Systemic Lupus Erythematosus
Pillai, R. K., Pillai, R. K., Illankovan, V. R., Balasubramaniam, V. R. M. T., Alabsi, A. M., Biswas, A., Darnal, H. K., Kayarohanam, S., Janakiram, M. K. S., & Subramaniyan, V. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70077 · Cited by 1
Restoring B cell intrinsic tolerance to lupus autoimmunity: a rational strategy for lupus treatment
Desikan, S., Chavan, S. V., Huan, E. Z., Kalin, P. M., Feuerman, M. H., Roman, C. A. J., & Huan, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728403 · Cited by 1
Sun, C., Wan, L., Gao, H., Ding, Y., Qu, Z., & Yu, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1791188 · Cited by 1
Immunometabolic modulators alleviate vascular dysfunction in mice with systemic lupus erythematosus
Miñano, S., Moleón, J., González‐Correa, C., Jiménez, R., Gómez‐Guzmán, M., Martín‐Morales, N., O’Valle, F., Romero, M., Toral, M., & Duarte, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117154 · Cited by 1
mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets
Huo, R., Chengcheng, W. E. I., Yang, Y., Meng, D., Yang, Y., & Huang, X. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s591631 · Cited by 1
Metabolic switch: lymphocytes and the onset of T-cell-mediated autoimmunity
Jahromi, A. M., Mirzaei, F., Mirzazadeh, S., Meri, S., Kabelitz, D., & Kalantar, K. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01460-5 · Cited by 1
Diagnosis and treatment directions and research frontiers of systemic lupus erythematosus
Jiang, N., Bai, W., Zhao, J., Zhang, S., Wu, C., Wang, L., Zhao, L., Li, J., Hu, C., Wang, Q., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0170 · Cited by 1
1205 Treatment of Lupus-prone BXSB Mice with a Modulatable CAR T cell System Targeting CD19
Rimann, I., Huang, H., Mace, P., González‐Quintial, R., Laborda, E., Viaud, S., Mora, H., Theofilopoulos, A. N., Young, T. S., & Kono, D. H. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-lupus21century.87 · Cited by 1
Lai, Z., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J. L., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-lupus21century.85 · Cited by 1
Self-citationMetabolic changes during evolution of Sjögren's in both an animal model and human patients
Jacob, A., He, J., Peck, A. B., Jamil, A. K., Bunya, V. Y., Alexander, J. J., & Ambrus, J. L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41082 · Cited by 1
Systemic Lupus Erythematosus: A Narrative Review of Disease
Barrouq, D. M. S., & Jibril, N. I. A. (2022) · East African Scholars Journal of Medical Sciences · doi:10.36349/easms.2022.v05i09.005 · Cited by 1
Zeng, H., Xie, Z., Luo, B., Liao, C., Hu, H., Wang, Z., & Ye, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-823763/v1 · Cited by 1
Sirolimus for systemic lupus erythematosus
Hu, H., Lee, F. J., & Garsia, R. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31792-6
Sirolimus for systemic lupus erythematosus – Authors' reply
Perl, A., Lai, Z., Kelly, R., Faraone, S. V., & Phillips, P. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31794-x
Self-citationAviña-Zubieta, J. A., Haag, H., Sayre, E. C., Esdaile, J. M., & Vera, M. A. D. (2018) · Lupus Science & Medicine · doi:10.1136/lupus-2018-lsm.27
Lai, Z., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J. L., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · Lupus Science & Medicine · doi:10.1136/lupus-2018-lsm.26
Self-citationMiyatake, D., Shibata, T., Shibata, M., Kaneko, Y., Oda, K., Nishimura, T., Katashima, M., Sekino, H., Furihata, K., & Urae, A. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-eular.2413
New treatments of systemic lupus erythematosus
Kyttaris, V. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00066-0
Perl, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00031-3
Self-citationImmunosuppressive therapy in SLE
Wise, L. M., & Stohl, W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00044-0
Hoi, A. Y.-B. (2021) · Springer eBooks · doi:10.1007/978-3-030-85161-3_8
1)楔フィルターの設計と線量分布について(Wedge Fielter)
藤田, 一., 鈴江, 正., & 河原, 良. (1963) · 日本放射線技術學會雜誌
Regulatory T cells in autoimmunity and potential therapeutic targets
Jindal, A. K., Banday, A. Z., & Tyagi, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00007-4
Repositioning drugs for systemic lupus erythematosus
Kingsmore, K. M., Lipsky, P. E., & Grammer, A. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00067-2
1204 Improving lymphatic function to reduce B cell responses in lupus
Ambler, W. G., Howlader, M. J., Chalasani, M. L. S., Seltzer, E. S., Sim, J., Shin, J., Schwartz, N., Dasoveanu, D., Carballo, C. B., Sevim, E., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-lupus21century.86
Abdel-Maksoud, M. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85831-1.00016-4
Liposomal aggregates sustain the release of rapamycin and protect cartilage from frictionPreprint
Bordon, G., Ramakrishna, S. N., Edalat, S. G., Eugster, R., Arcifa, A., Aleandri, S., Frank‐Bertoncelj, M., Isa, L., Crockett, R., Distler, O., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.23.533793
Blagov, A. V., Zhuravlev, A. D., Sukhorukov, V. N., Popov, M. A., Grechko, A. V., & Orekhov, A. N. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231194240
Metabolic control of immunopathogenesis in systemic lupus erythematosus
Perl, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00023-x
Self-citationRole of regulatory T cells in pathogenesis and therapeutics of systemic lupus erythematosus
Ríos-Ríos, W. D. J., & Aguilar, H. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00030-0
Role of regulatory T cells in the pathogenesis and therapeutics of primary Sjögren’s syndrome
Xu, X., & Lin, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00029-4
Sex differences in regulatory T cells during autoimmune disease
Weigel, G. J., Beetler, D. J., & Fairweather, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00004-x
Precision mitochondrial medicine: Uncovering pathways across diverse diseases
Sainero‐Alcolado, L., Garde-Lapido, E., Liaño-Pons, J., & Arsenian‐Henriksson, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00007-2
Hanson, E., Berner, K., & Berner, J. E. (2025) · Cureus · doi:10.7759/cureus.79268
Investigating the effect of metformin on disease activity in systemic lupus erythematosus
Rathi, L., Ameer, A., Mehmood, F., Abdalla, A., Suliman, M., Aakash, A., Aslam, N., Kumar, S., & Ismail, H. (2025) · Journal of Carcinogenesis · doi:10.64149/j.carcinog.24.10s.122-128
Wang, Y.-Y., Zou, L.-P., Xu, K.-F., Xu, W.-S., Zhang, M.-N., Lu, Q., Tian, X.-L., Pang, L.-Y., He, W., Wang, Q.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26761662
Management strategies for systemic lupus erythematosus using kinase inhibitors
Liao, K., Lee, H. J., & Morand, E. F. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.08
Pei, Y., Zhou, Y., Yang, F., Cao, L., Yao, R., Liang, R., Han, X., Wang, X., Liu, Z., Zhu, J., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119101
Sirolimus-based induction therapy for lupus nephritis: A single-arm, open-label pilot clinical trial
Zou, B., & Yang, P. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0019
Drug Repurposing to Improve the Treatment of Rheumatic Autoimmune Inflammatory Diseases
Talukder, P., Sengupta, S., Sultana, S., Das, S., & Nandi, A. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814533126010008
Bakay, U. (2026) · Rheumatology and Immunology Research · doi:10.1515/rir-2026-0009
Mielle, J. (2018) · theses.fr (ABES) · doi:10.70675/97ba80d1z789ez4813zabfbz668b70bf3519
Pathogenesis-directed lupus therapeutics
Poudyal, B., & Perl, A. (2026) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001160
Self-citationThe role of O-GlcNAcylation in the pathophysiology of Systemic Lupus Erythematosus
Galli, G. (2022) · theses.fr (ABES) · doi:10.70675/db863337z7c69z4a5dz9e94z7163b54542ee
An Update Comprehensive Review on Epigenetic Modifications and Therapies in Autoimmune Diseases
Chen, H., Zhou, S., Ji, F., Chen, K., Jian, L., Wang, Y., Yao, H., Yang, M., & Wu, H. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09133-x
Double-negative T cells in systemic lupus erythematosus: From immunopathology to therapeutic target
Zhao, Y., Liu, X., Li, N., Liu, J., Gao, C., & Wang, C. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104077
Gaspar, P., Ribeiro, F., Fonseca, V. R., Romão, V. C., Fonseca, J. P. A., & Graça, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104112
Jiang, M., Zhang, F., Ren, M., Li, Z., Xie, Z., & Sun, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841513
Immunometabolism of systemic lupus erythematosus
Furment, M. M., & Perl, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00042-1
Self-citationAccelerated immunosenescence in SLE: current evidence and clinical translation
Li, Q., Zhang, W., Chen, Y., & Du, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1830804
Metabolic determinants of autoimmune kidney diseases
Scindia, Y., & Morel, L. M. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01096-8
Hillal, J. P. D., Weber, T. A., Staub, H. L., & Bauer, M. E. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104144
Programmed cell death in autoimmune diseases
Cai, X., & Yao, Y. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104145
Joshi, M. V., Hofland, U., & Morel, L. M. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104146
Senescence of the immune system in SLE: Pathogenic mechanisms and therapeutic implications
Jiang, X., Liang, Z., Zhao, C., Li, F., Su, Q., Wang, Y., Zhang, S., & Cheng, T. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104152
Metadata
- Authors
- Lai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., Faraone, S. V., Phillips, P. E., & Perl, A.
- Affiliations
- SUNY Upstate Medical University (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 391
- Issue
- 10126
- Pages
- 1186-1196
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5891154
- OpenAlex
- W2791734424
- Cited by
- 412
- References
- 43
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 51 · 2023: 35 · 2022: 67 · 2021: 44 · 2020: 56 · 2019: 49 · 2018: 31
- FWCI
- 38.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- Syracuse University
- National Institute of Allergy and Infectious Diseases (R01AI048079, R01AI122176, R56AI048079, R01AI072648, R34AI141304)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- rapamycin, systemic lupus erythematosus, mTOR inhibition, T cell dysfunction, refractory lupus, disease activity, BILAG index, SLEDAI, drug safety and tolerability, biomarker-driven treatment, mTOR inhibitors, immunosuppressive therapy, dose adjustment, adverse events, lupus nephritis, proteinuria, thrombocytopenia
- MeSH terms
- Adolescent, Adult, Aged, Drug Tolerance, Female, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Treatment Outcome, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
